Pharmaceuticals News and Research

RSS

FDA approves Meda's ASTEPRO Nasal Spray

Meda Pharmaceuticals Inc. today announced that the US Food and Drug Administration (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for the treatment of the symptoms of seasonal and perennial allergic rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% is the first nasal antihistamine to offer convenient once-daily dosing for patients who suffer from seasonal allergies.

2 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

Validus chooses Ranbaxy to market an authorized generic version of Rocaltrol in the US

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with Validus Pharmaceuticals LLC (Validus) to market and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral liquid formulation. Overall market sales for calcitriol softgel capsules and oral liquid were $70 million (IMS - MAT: June 2009).

2 Sep 2009

Analytical Technologies division of MDS to be acquired by Danaher

Danaher Corporation (NYSE: DHR) today announced that it has signed a definitive agreement with MDS Inc. (TSX: MDS; NYSE: MDZ) to acquire the Analytical Technologies division of MDS, which includes a 50% ownership position in Applied Biosystems/MDS Sciex joint venture ("AB SCIEX"), a mass spectrometry business, and a 100% ownership position in the former Molecular Devices Corporation, a bioresearch and analytical instrumentation company.

From Danaher 2 Sep 2009

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

A groundbreaking new treatment for obesity is to begin clinical trials in January. Madrona Ventures Inc., an American publicly listed company (OTCBB:MDRV), has acquired the treatment's European patent and the pending American patent application.

2 Sep 2009

Strategy to enhance diabetes management across Canada

Research being driven by The University of Western Ontario that will enhance diabetes management across Canada recently received support from two of Canada's leading pharmaceutical companies in the form of a $500,000 contribution.

2 Sep 2009

Lupus Foundation of America to educate people with lupus on clinical trial participation

It has been more than 50 years since the U.S. Food and Drug Administration (FDA) last approved a new medicine specifically for lupus – when Dwight D. Eisenhower was president. Existing treatments have been "borrowed" from other disorders and the risk/benefit ratio of these treatments is far from optimal. However, hope is on the horizon.

2 Sep 2009

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

Government, medical and community experts to discuss about prevention and detection of viral hepatitis

To address this public health challenge, government, medical and community experts will meet September 10-11 in Washington, D.C. to plan an improved national response to viral hepatitis. The conference "The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C" will feature keynote addresses, panel discussions and scientific poster sessions focused on enhancing the prevention and detection of viral hepatitis and improving care for people who are already living with the disease.

2 Sep 2009

Actelion launches new 20 mcg/mL Ventavis formulation

Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.

2 Sep 2009

Mylan's subsidiary launches levalbuterol inhalation solution used for treating bronchospasm

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP (Concentrate), 0.25%, (1.25 mg/0.5 mL). Mylan, which has already launched the product, will market this product with 180 days of exclusivity.

2 Sep 2009

Pathogenic microbes can suppress immune system in newborns

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

2 Sep 2009

Single-dose H1N1 vaccine wins approval in China

The Chinese biopharmaceutical company Sinovac Biotech Ltd. on Monday announced its H1N1 (swine) flu vaccine won the approval of a panel of experts from China's State Food and Drug Administration, the Associated Press/Forbes reports. The company expects to obtain a production license later this week. According to the company, clinical trials of the H1N1 vaccine showed a single shot produced an immune response capable of protecting against H1N1 (8/31).

2 Sep 2009

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism. Bile acid activation of the G protein-coupled receptor TGR5 has been shown to induce energy expenditure in muscle and brown fat, thereby conferring resistance to weight gain.

2 Sep 2009

Ariba podcast to help pharmaceutical companies conduct cost-effective sourcing

With expiring patents and growing gaps in revenue a reality in today’s global pharmaceutical industry, an increasing number of drug manufacturers are beginning to evaluate their supply chains to identify any and all opportunities for savings so that they can continue to bring innovative products to market and remain competitive.

1 Sep 2009

Fox Chase becomes the seventh cancer center to receive the CEO Cancer Gold Standard accreditation

Fox Chase Cancer Center has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.

1 Sep 2009

Endosense raises USD 36 million in Series B financing

Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing. Edmond de Rothschild Investment Partners (EdRIP) led the round, with additional participation from Neomed, Gimv, VI Partners (VI), Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.

1 Sep 2009

Dr. Raman Bedi to exclusively represent Oragenics' oral care products

Florida-based biopharmaceutical leader Oragenics, Inc. has appointed renowned international oral care authority Dr. Raman Bedi to serve as exclusive representative for the company’s award-winning line of oral care products to the Middle East.

1 Sep 2009

Intrexon purchases assets and operations of Avalon Pharmaceutical

Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the purchase of assets and operations of Avalon Pharmaceutical, Inc., a wholly-owned subsidiary of Clinical Data, Inc.

1 Sep 2009

Clinical Data raises funds by selling certain assests to Intrexon Corporation

Clinical Data, Inc. (NASDAQ: CLDA) today announced the sale of certain assets to Intrexon Corporation, a transaction that is consistent with the Company’s ongoing plan to focus resources on its valuable late-stage and preclinical drug programs.

1 Sep 2009

Pharmaceuticals News and Research

FDA approves Meda's ASTEPRO Nasal Spray

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Validus chooses Ranbaxy to market an authorized generic version of Rocaltrol in the US

Analytical Technologies division of MDS to be acquired by Danaher

Patents for treatment for obesity acquired by Madrona Ventures, to start clinical trials soon

Strategy to enhance diabetes management across Canada

Lupus Foundation of America to educate people with lupus on clinical trial participation

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Government, medical and community experts to discuss about prevention and detection of viral hepatitis

Actelion launches new 20 mcg/mL Ventavis formulation

Mylan's subsidiary launches levalbuterol inhalation solution used for treating bronchospasm

Pathogenic microbes can suppress immune system in newborns

Single-dose H1N1 vaccine wins approval in China

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Ariba podcast to help pharmaceutical companies conduct cost-effective sourcing

Fox Chase becomes the seventh cancer center to receive the CEO Cancer Gold Standard accreditation

Endosense raises USD 36 million in Series B financing

Dr. Raman Bedi to exclusively represent Oragenics' oral care products

Intrexon purchases assets and operations of Avalon Pharmaceutical

Clinical Data raises funds by selling certain assests to Intrexon Corporation

Event guide: World ADC San Diego eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring